oral GLP-1 and AI pipeline undervalued
POLB is framed as a micro-cap with a large AI-driven oral GLP-1 weight-loss program and additional cancer-treatment AI initiatives, where the speaker expects a large revenue/profit ramp that could justify dramatic upside from today’s scale.
This micro-cap is advancing an AI-driven oral GLP-1 weight-loss program alongside cancer-treatment initiatives, with an anticipated revenue and profit ramp that could justify dramatic appreciation from today’s small base. The density of AI-enabled catalysts relative to current market scale anchors the bull case.
"These 2 Stocks Will Make Me A Billionaire by 2028! NASDAQ: RXRX, LON: POLB!"